Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Novel variant c.428T>C in FZD4 gene in a pedigree affected by familial exudative vitreoretinopathy: clinical, functional, and structural characterization.

Ophthalmic genetics·2026

Same author

Immunotoxicity and mechanism analysis of zebrafish embryos exposure to benzothiazole and its derivatives.

Comparative biochemistry and physiology. Toxicology & pharmacology : CBP·2025

Same author

Discovery of imidazo[1,2-a]pyridine derivatives as potent anti-influenza agents: SPR affinity-based screening and structure-activity relationship study.

European journal of medicinal chemistry·2025

Same author

IL-8/CXCR2 mediates resistance to apatinib through PI3K/AKT and vasculogenic mimicry in gastric cancer cells.

Tissue & cell·2025

Same author

[Textual study of Baihuasheshecao (Hedyotis diffusa)].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2025

Same author

<i>GNA13</i> promotes brain metastasis of non-small cell lung cancer and EMT through the WNT/β catenin signaling pathway.

Frontiers in cell and developmental biology·2025

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Triptolide functions as a potent angiogenesis inhibitor.

Ming-Fang He¹, Yi-Hsien Huang, Li-Wha Wu

¹Department of Biology, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, People's Republic of China.

International Journal of Cancer

|July 2, 2009

Summary

Triptolide, a compound from Tripterygium wilfordii, inhibits angiogenesis by blocking Tie2 and VEGFR-2 signaling pathways. This suggests its potential as an antiangiogenic agent for cancer therapy.

More Related Videos

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

Related Experiment Videos

Last Updated: Jun 22, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

Area of Science:

Pharmacology
Molecular Biology
Cancer Research

Background:

Triptolide is a potent anti-inflammatory and antitumor compound derived from Tripterygium wilfordii Hook. f.
Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and progression.

Purpose of the Study:

To investigate the antiangiogenic properties of triptolide.
To elucidate the underlying molecular mechanisms of triptolide's antiangiogenic effects.

Main Methods:

In vitro and in vivo angiogenesis assays (Matrigel plug assay, murine tumorigenesis assay).
Semiquantitative RT-PCR and Western blot analysis to assess Tie2 and VEGFR-2 expression.
Endothelial cell proliferation and network formation assays.
Tie2 overexpression and knockdown experiments.

Main Results:

Triptolide demonstrated potent inhibition of angiogenesis in vitro (IC50 = 45 nM) and in vivo.
Triptolide significantly blocked tumor angiogenesis and progression in a murine model.
Mechanism involves downregulation of proangiogenic Tie2 and VEGFR-2 expression in endothelial cells.
Tie2 signaling plays a significant role in triptolide's antiangiogenic effects.

Conclusions:

Triptolide exhibits significant antiangiogenic activity, contributing to its antitumor effects.
The compound acts by inhibiting endothelial receptor-mediated signaling pathways, specifically Tie2 and VEGFR-2.
Triptolide holds promise as a novel antiangiogenic agent for cancer treatment.